U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

Dow Jones04-15

0955 GMT - A U.S. investigation into pharmaceutical imports and potential tariffs in the coming months will likely limit clarity from pharma companies during their 1Q results, Barclays analysts say in a note. The investigation, initiated April 1, aims to assess the national security implications of pharmaceutical imports, including finished generics, nongenerics and active pharmaceutical ingredients, and has to be finalized in around nine months. "With Pharma having been excluded from the initial reciprocal tariffs and it being our house view that some sort of Commerce Department investigation being required for these sectoral tariffs, this isn't too surprising but at least provides some timing framing," they say. Barclays analysts estimate that AstraZeneca, Roche and Grifols appear most insulated, whereas ​GSK and Sandoz look most exposed to a potential tariff risk. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

April 15, 2025 05:55 ET (09:55 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment